SCHEMBL5222076

SCHEMBL5222076

Cc1nc(-c2ccc(-c3ccc(CN4CCC(N5CCN(C)CC5)C4)cc3)cc2)no1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.45
GPR119 Q8TDV5 1/20 0.45
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 2/20 0.42
RAB9A P51151 2/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
TSHR P16473 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HSD17B10 Q99714 1/20 0.42
MITF O75030 1/20 0.42
S1PR1 P21453 8/20 0.41
S1PR5 Q9H228 7/20 0.41
S1PR4 O95977 6/20 0.41
CHKA P35790 1/20 0.40
CXCR1 P25024 1/20 0.40
S1PR3 Q99500 3/20 0.39
HRH3 Q9Y5N1 1/20 0.39
PIK3CA P42336 1/20 0.39
MTOR P42345 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5222060 1.00 KCNH2 (0.45) KCNH2GPR119KDM4EALDH1A1RAB9A
SCHEMBL5928064 0.91 KCNH2 (0.46) KCNH2GPR119ALDH1A1RAB9ALMNA
SCHEMBL5225048 0.90 RAB9A (0.46) KCNH2GPR119ALDH1A1RAB9ALMNA
SCHEMBL5225059 0.90 RAB9A (0.46) KCNH2GPR119ALDH1A1RAB9ALMNA
SCHEMBL5220668 0.89 RAB9A (0.46) KCNH2GPR119ALDH1A1RAB9ALMNA
SCHEMBL5220653 0.89 RAB9A (0.46) KCNH2GPR119ALDH1A1RAB9ALMNA
SCHEMBL5224071 0.83 S1PR1 (0.47) KCNH2GPR119ALDH1A1RAB9ALMNA
SCHEMBL5228387 0.82 RAB9A (0.51) KCNH2GPR119ALDH1A1RAB9ALMNA
SCHEMBL5224061 0.81 NPC1 (0.49) KCNH2GPR119ALDH1A1RAB9ALMNA
SCHEMBL5224103 0.80 LTA4H (0.46) KCNH2GPR119ALDH1A1RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060019998-A1 Histamine-3 receptor antagonist PFIZER INC 2006-01-26 US claimed
EP-1771449-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS Pfizer Products Incorporated (US) 2007-04-11 EP disclosed
WO-2006011043-A1 HISTAMINE-3 RECEPTOR ANTAGONISTS PFIZER PRODUCTS INC. (US) 2006-02-02 WO disclosed
US-20060019998-A1 Histamine-3 receptor antagonist PFIZER INC 2006-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019998-A1 Histamine-3 receptor antagonist HRH3, HRH4, HRH2 KCNH2 909/4885GPR119 34/4885KDM4E 3277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.